Studies of human placental aromatase
Kinetic analysis of aromatization of androstenedione ( Δ 4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El....
Gespeichert in:
Veröffentlicht in: | Journal of steroid biochemistry 1975-03, Vol.6 (3), p.317-322 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 322 |
---|---|
container_issue | 3 |
container_start_page | 317 |
container_title | Journal of steroid biochemistry |
container_volume | 6 |
creator | Siiteri, Pentti K. Thompson, E.Aubrey |
description | Kinetic analysis of aromatization of androstenedione (
Δ
4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome
c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both
in vitro and
in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action. |
doi_str_mv | 10.1016/0022-4731(75)90149-1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_83063081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0022473175901491</els_id><sourcerecordid>83063081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhrPwPvoGs-hCRBfV3Jo0G0EGbzDgQl2HJD3BSC9j0gq-va0dZunqwPkv8H8ILQm-JpiIG4wpzblk5FIWVwoTrnKyh4537yN0ktInxkSVnB6ig5JgQcUxOn_thypAyjqffQyNabNNbRy0vakzE7vG9CbBKdr3pk5wtr0L9P5w_7Z6ytcvj8-ru3XuWCH6vDCKcme8AUsdod4rT42QVHhg1DIqFeNcWaxsxaUCX3LLeeWKwkrpxghboIu5dxO7rwFSr5uQHNS1aaEbki4ZFgyXZDTy2ehil1IErzcxNCb-aIL1xENPw_U0XMtC__HQU2y57R9sA9UuNMMY5dtZhnHjd4CokwvQOqhCBNfrqgv_9_8CqK1v0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83063081</pqid></control><display><type>article</type><title>Studies of human placental aromatase</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Siiteri, Pentti K. ; Thompson, E.Aubrey</creator><creatorcontrib>Siiteri, Pentti K. ; Thompson, E.Aubrey</creatorcontrib><description>Kinetic analysis of aromatization of androstenedione (
Δ
4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome
c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both
in vitro and
in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action.</description><identifier>ISSN: 0022-4731</identifier><identifier>DOI: 10.1016/0022-4731(75)90149-1</identifier><identifier>PMID: 810626</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Androstenedione ; Animals ; Aromatase ; Aromatase Inhibitors ; Cyanides - pharmacology ; Cytochrome P-450 Enzyme Inhibitors ; Female ; Humans ; Kinetics ; Microsomes - drug effects ; Microsomes - enzymology ; NADPH-Ferrihemoprotein Reductase - antagonists & inhibitors ; Ovary - enzymology ; Oxidoreductases ; Placenta - drug effects ; Placenta - enzymology ; Placenta - ultrastructure ; Rats ; Testolactone - analogs & derivatives ; Testolactone - pharmacology ; Testosterone - analogs & derivatives ; Testosterone - pharmacology</subject><ispartof>Journal of steroid biochemistry, 1975-03, Vol.6 (3), p.317-322</ispartof><rights>1975</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</citedby><cites>FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/810626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Siiteri, Pentti K.</creatorcontrib><creatorcontrib>Thompson, E.Aubrey</creatorcontrib><title>Studies of human placental aromatase</title><title>Journal of steroid biochemistry</title><addtitle>J Steroid Biochem</addtitle><description>Kinetic analysis of aromatization of androstenedione (
Δ
4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome
c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both
in vitro and
in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action.</description><subject>Androstenedione</subject><subject>Animals</subject><subject>Aromatase</subject><subject>Aromatase Inhibitors</subject><subject>Cyanides - pharmacology</subject><subject>Cytochrome P-450 Enzyme Inhibitors</subject><subject>Female</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Microsomes - drug effects</subject><subject>Microsomes - enzymology</subject><subject>NADPH-Ferrihemoprotein Reductase - antagonists & inhibitors</subject><subject>Ovary - enzymology</subject><subject>Oxidoreductases</subject><subject>Placenta - drug effects</subject><subject>Placenta - enzymology</subject><subject>Placenta - ultrastructure</subject><subject>Rats</subject><subject>Testolactone - analogs & derivatives</subject><subject>Testolactone - pharmacology</subject><subject>Testosterone - analogs & derivatives</subject><subject>Testosterone - pharmacology</subject><issn>0022-4731</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1975</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxDAUhrPwPvoGs-hCRBfV3Jo0G0EGbzDgQl2HJD3BSC9j0gq-va0dZunqwPkv8H8ILQm-JpiIG4wpzblk5FIWVwoTrnKyh4537yN0ktInxkSVnB6ig5JgQcUxOn_thypAyjqffQyNabNNbRy0vakzE7vG9CbBKdr3pk5wtr0L9P5w_7Z6ytcvj8-ru3XuWCH6vDCKcme8AUsdod4rT42QVHhg1DIqFeNcWaxsxaUCX3LLeeWKwkrpxghboIu5dxO7rwFSr5uQHNS1aaEbki4ZFgyXZDTy2ehil1IErzcxNCb-aIL1xENPw_U0XMtC__HQU2y57R9sA9UuNMMY5dtZhnHjd4CokwvQOqhCBNfrqgv_9_8CqK1v0g</recordid><startdate>197503</startdate><enddate>197503</enddate><creator>Siiteri, Pentti K.</creator><creator>Thompson, E.Aubrey</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197503</creationdate><title>Studies of human placental aromatase</title><author>Siiteri, Pentti K. ; Thompson, E.Aubrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1975</creationdate><topic>Androstenedione</topic><topic>Animals</topic><topic>Aromatase</topic><topic>Aromatase Inhibitors</topic><topic>Cyanides - pharmacology</topic><topic>Cytochrome P-450 Enzyme Inhibitors</topic><topic>Female</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Microsomes - drug effects</topic><topic>Microsomes - enzymology</topic><topic>NADPH-Ferrihemoprotein Reductase - antagonists & inhibitors</topic><topic>Ovary - enzymology</topic><topic>Oxidoreductases</topic><topic>Placenta - drug effects</topic><topic>Placenta - enzymology</topic><topic>Placenta - ultrastructure</topic><topic>Rats</topic><topic>Testolactone - analogs & derivatives</topic><topic>Testolactone - pharmacology</topic><topic>Testosterone - analogs & derivatives</topic><topic>Testosterone - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siiteri, Pentti K.</creatorcontrib><creatorcontrib>Thompson, E.Aubrey</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of steroid biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siiteri, Pentti K.</au><au>Thompson, E.Aubrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Studies of human placental aromatase</atitle><jtitle>Journal of steroid biochemistry</jtitle><addtitle>J Steroid Biochem</addtitle><date>1975-03</date><risdate>1975</risdate><volume>6</volume><issue>3</issue><spage>317</spage><epage>322</epage><pages>317-322</pages><issn>0022-4731</issn><abstract>Kinetic analysis of aromatization of androstenedione (
Δ
4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome
c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both
in vitro and
in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>810626</pmid><doi>10.1016/0022-4731(75)90149-1</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-4731 |
ispartof | Journal of steroid biochemistry, 1975-03, Vol.6 (3), p.317-322 |
issn | 0022-4731 |
language | eng |
recordid | cdi_proquest_miscellaneous_83063081 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Androstenedione Animals Aromatase Aromatase Inhibitors Cyanides - pharmacology Cytochrome P-450 Enzyme Inhibitors Female Humans Kinetics Microsomes - drug effects Microsomes - enzymology NADPH-Ferrihemoprotein Reductase - antagonists & inhibitors Ovary - enzymology Oxidoreductases Placenta - drug effects Placenta - enzymology Placenta - ultrastructure Rats Testolactone - analogs & derivatives Testolactone - pharmacology Testosterone - analogs & derivatives Testosterone - pharmacology |
title | Studies of human placental aromatase |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A23%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Studies%20of%20human%20placental%20aromatase&rft.jtitle=Journal%20of%20steroid%20biochemistry&rft.au=Siiteri,%20Pentti%20K.&rft.date=1975-03&rft.volume=6&rft.issue=3&rft.spage=317&rft.epage=322&rft.pages=317-322&rft.issn=0022-4731&rft_id=info:doi/10.1016/0022-4731(75)90149-1&rft_dat=%3Cproquest_cross%3E83063081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=83063081&rft_id=info:pmid/810626&rft_els_id=0022473175901491&rfr_iscdi=true |